A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of ...
Zacks Investment Research on MSN
United Therapeutics stock surges 32% in 6 months: Here's why
Shares of United Therapeutics UTHR have surged approximately 32% over the past six months, driven by strong commercial growth, a major clinical breakthrough and improved long-term growth visibility, ...
Hosted on MSN
This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside
United Therapeutics Corporation (UTHR) announced on Tuesday that its study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) ...
Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF Subjects will be randomly allocated 1:1 to receive Tyvaso or placebo. All subjects will initiate Tyvaso or ...
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression “Completing enrollment in this trial brings us one step ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...
Arteries are blood vessels that carry blood away from your heart. Pulmonary arterial hypertension (PAH) is a condition where you have high blood pressure in the arteries that go from your heart to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results